N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=76 Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
Liver Cancer · Hepatocellular Carcinoma
Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants
Phase 2 N=20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Childhood Hepatocellular Carcinoma · Papillary Thyroid Cancer · Previously Treated Childhood Rhabdomyosarcoma
Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
Phase 2 N=18 Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Dose-limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of Belinostat in Patients With Inoperable HCC (Phase I) — 0; 0; 0; 1 Participants
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Phase 2 N=13 Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
Advanced Hepatocellular Carcinoma · BCLC Stage A Hepatocellular Carcinoma · BCLC Stage B Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 23.1 percentage of participants
Phase 2 N=97 A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
Phase 2 N=40 Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Hepatocellular Cancer
Primary: Time to Progression — 7.7 Months
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants
N/A N=402 HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma
Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
Phase 3 N=602 A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 324; 241 days — p=0.00583
Phase 2 N=21 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants